Allergy Therapeutics Share Discussion Threads

[wigwammer] 01/4/2019 14:14

Jimmy - I agree, they hit a disappointment. Rather different at this juncture however, to buy into a company that has halved because of a disappointment, than to buy into a company that has halved because it is pulling the wool over your eyes and is in the process of being found out.

[jimmyloser] 01/4/2019 13:45

wigwammer,
As they have both stated how shocked they were with another duster set of trial results, I think that you can read that they expected their purchases to go to nearer 30p than the shocking -8p that we have fallen to

It will recover unless we have more dreadful news and with AGY that just cannot be ruled out.

impo/dyor

[wigwammer] 01/4/2019 13:20

Yes, a £26k purchase by the FD is a meaningful sum. We are in agreement :)

[arthur_lame_stocks] 01/4/2019 12:44

Huge investment for the very well paid to make, I'm sure you'll agree.

[wigwammer] 01/4/2019 11:52

Strange thing for the management of a company with no future to do at double the current price. "24 October 2018 - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer and Nick Wykeman, Chief Financial Officer, have today purchased 50,000 and 150,000 ordinary shares, respectively, of 0.1 pence each in the Company ("Ordinary Shares"), at a price of 17.5 pence per Ordinary Share. Furthermore, Peter Jensen, Non-Executive Chairman, has today purchased 20,000 Ordinary Shares at a price of 18 pence per Ordinary Share."

[arthur_lame_stocks] 31/3/2019 10:10

I reckon you ought to be careful spooky, look at the huge deficit on the P&L, this company has never really made a profit as far as I can see.

[spooky] 31/3/2019 09:52

Just for the record, i have bought a reasonable number.

[eltorres70] 29/3/2019 12:04

@Maddox Well, ALK has already registered tablets for dust mites, trees, grass and venoms. Stallergenes has registered dust mites and grass. PLUS other companies are way way far ahead with development of tablets for peanut allergies. Following this failure, which proves their products being ineffective (they have NO RELEVANT REGISTERED PRODUCTS)... the only conclusion is quite logic. They have no future.
Even directors don’t believe they have a future. Where are they now? No one is buying because they know the company is in BIG trouble.

[nquaile875] 28/3/2019 17:26

The key point was December 2018. When the share price levelled at 13-14p and prior to the Birch Trial Phase III results you would have expected some form of PDMR buys if they had confidence in the trials and the long term share price achieveing around 40p+. The fact that there have been none,(last was October 2018 with 3 directors buying at around 17.5p), and then the failure of Phase III is all the indication you need. I'm not convinced this is a buy and tuck away or a target for takeover, though Hardman & Co. keep pumping this in their reports! Caution advised imo/dyor

[maddox] 28/3/2019 11:15

Hi eltorres,

Whom are these competitors that are light years ahead?

[spooky] 26/3/2019 09:19

Not sure that is a great plan for long term wealth and happiness but it may work. Still a little surprised that there hasn't been ANY director buying following the falls.

[fillipe] 26/3/2019 09:13

Could be some useful gains to be had here by taking AGY at the present 5yrs+ low and just locking away for news of even modest progress.

On any suchlike AGY will always be ramped the "high heaven" and holders will be slipping out quietly with respectable gains.

f

[eltorres70] 22/3/2019 12:12

How can anyone still believe in this company when all they do is fail and put smoke in people’s eyes, they’ve been doing this for the past 10 years and that’s a fact. And the regression of their share price is hard proof. Finncap is the same source that was suggesting 40p before people lost loads of money. Birch trial proved ineffectiveness of all their current injectible treatments. They have no viable plans for the future, competitors are already light years ahead. Only a naive speculator can still believe the tales they’re telling.

[fillipe] 22/3/2019 10:08

jimmy, I only just now noticed that finnCap new target price of 40p that's rather encouraging, I felt.....particularly for new buyers at the current low.

f

[jimmyloser] 22/3/2019 09:05

Excellent note from FINNCAP this morning, they lower their target to 40p stating that Birch only accounts for 2 to 3 million revenues.


We are where we are! Now get us out of this deep hole!

[blather1] 21/3/2019 14:27

Yep....68 millions is indeed a small sum for a pharma outfit. But that is what could make it exceedingly attractive to buy at 08 pence! Plus allergies of all sorts tend to be illnesses of the developed (and wealthy) world.....meanwhile the underdeveloped world is Catching the rest of the world up. They also might, at that valuation look pretty attractive to take over surely?

[eltorres70] 21/3/2019 10:21

68millions is nothing for a pharmaceutical company. Especially in the wake of such a failure which proves inefficacy for products which are already on the market. I foresee devastating effects on revenue & their US registration plans

[spooky] 20/3/2019 10:53

Fairly surprised that there hasn't been any director buying down here, can't see anything that would be stopping them.

[wigwammer] 20/3/2019 09:51

"Their products are useless and will never be approved.." They sold around £68m of product last year :)

[jimmyloser] 20/3/2019 07:07

Similarities?

Itsy bitsy spider went up the water spout
Down came the rain
And washed the spider out
Out came the sun and dried up all the rain
And the itsy bitsy spider went up the spout again

[beccasan] 19/3/2019 10:08

I found these on another board:

hxxps://www.pulmonologyadvisor.com/aaaai-2019/asthma-with-comorbid-allergic-rhinitis-quality-of-life-improved-with-dupilumab/article/835609/

hxxps://www.clinicaladvisor.com/allergy-and-immunology-information-center/desensitizing-pediatric-peanut-allergy-with-oral-immunotherapy-ar101/article/818585/

Makes me wonder if there is any future for AGY after this huge fall, in a market that seems to be leading allergy treatment in a completely different direction, far away from traditional immunotherapy and its potentially dangerous adverse reactions.

[eltorres70] 18/3/2019 21:23

----
“Manuel Llobet, CEO at Allergy Therapeutics, stated: "We are surprised by the result, given the strong immune response suggested by the increased immunoglobulin markers in the treatment arm and the substantial symptom improvement we had observed in earlier trials. We will now undertake a comprehensive review of the full dataset to determine our path forward with the investigational product. As a science-driven company we are conscious at Allergy Therapeutics of the challenges regarding subjective measures in allergy field studies. We are committed to overcoming these challenges and bringing this new product to market."
Allergy Therapeutics has extensive experience with other approved and commercialized birch products. Since 2010, the investigational product has undergone two successful Phase II trials where a highly statistically significant 32% reduction in allergic symptoms between the active and placebo was observed. The Group will undertake a review of the full trial dataset to understand any cause for the lack of consistency in the clinical outcomes seen between the studies.”
----

It is common knowledge in scientific trials that immunoglobulin markers increase with this kind of injectable drugs. (In fact, Circassia had the same exact results with immunoglobulin markers increase in phase II but inconclusive outcomes in stage III). The fact that there was a immunoglobulin response has NO predictive value to the trial for these products, same applies for the other trials they currently have in Phase II. I don’t understand why they keep telling this story to people.

[jimmyloser] 18/3/2019 17:04

Hardman, an attempt at damage limitation? Well for what it is worth, I for one have been very damaged by to-days unexpected news.